Genmab A/S(Nasdaq: GMAB) announced today thatit will discontinue further clinical development of acasunlimab. This decision was made as part of Genmab’s strategic focus on the most value‑creating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback